An observational study in Hemophilia, sponsored by Investigación en Hemofilia y Fisioterapia. Completed at 1 site in Spain. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Investigación en Hemofilia y Fisioterapia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Hemophilia A by Investigación en Hemofilia y Fisioterapia — 5 open to participants now, 6 under way, none of them phase 3. Hemophilia A · Investigación en Hemofilia y Fisioterapia.
Among the 21 studies in Hemophilia A by Investigación en Hemofilia y Fisioterapia, this one is one of 4 that started in 2025, is one of 9 observational ones, and was the 16th registered.
845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.
Browse Hemophilia A studies →5 of the 21 studies in Hemophilia A by Investigación en Hemofilia y Fisioterapia are open now, in 1 country. Recruiting first, the newest first:
Investigación en Hemofilia y Fisioterapia · Sites in Spain
Ages 18+ · Men only
Investigación en Hemofilia y Fisioterapia · Sites in Spain
Ages 18–65 · Men only · Healthy volunteers
Investigación en Hemofilia y Fisioterapia · Sites in Spain
Ages 18+ · Men only
Investigación en Hemofilia y Fisioterapia · Sites in Spain
Ages 18+ · Men only
Investigación en Hemofilia y Fisioterapia · Sites in Spain
Ages 10+ · Men only
By country, each count listing its studies:
Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 4 started in 2025.
This study's enrollment of 114 is above the median of 81 across 311 observational studies indexed under Hemophilia A.
Median enrollment 36 across the 12 interventional studies, 70 across the 9 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Investigación en Hemofilia y Fisioterapia is the lead sponsor of 57 studies on the registry; 6 are open to participants now.
1 of the studies in Hemophilia A by Investigación en Hemofilia y Fisioterapia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07420387Investigación en Hemofilia y FisioterapiaEffectiveness of an Educational Program for Pain Management in Patients With Hemophilic Arthropathy | 2027-06-28 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Hemophilia A by Investigación en Hemofilia y Fisioterapia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Introduction: Hemophilia is a congenital coagulopathy characterised by recurrent haemarthrosis, leading to chronic arthropathy and functional impairment. Prophylactic treatment with extended half-life (EHL) or short half-life (SHL) clotting factor concentrates is the most effective strategy for preventing these episodes. EHL products have demonstrated haemostatic efficacy, with a lower frequency of infusions, potentially reducing the treatment burden, although their psychosocial impact has not yet been sufficiently explored.
Objectives: To evaluate the association between perceived treatment burden and psychosocial variables such as self-efficacy, adherence, sleep quality and health locus of control, depending on the type of treatment received (EHL or SHL).
Methods. Multicentre, ambispective cohort study. A total of 114 patients with haemophilia A or B undergoing EHL or SHL prophylactic treatment will be included. The primary variable will be treatment burden (Treatment Burden Questionnaire). Secondary variables will be perceived self-efficacy (General Self-Efficacy Scale), adherence (Torres scale), sleep quality (Pittsburgh Sleep Quality Index), treatment adherence (Torres Questionnaire) and health locus of control (Multidimensional Health Locus of Control). Potential confounding variables will include sociodemographic data (age, educational level, living arrangements) and clinical data (number of weekly infusions, type of hospital).
Expected results: Patients treated with extended-half-life products are expected to report lower treatment burden, higher self-efficacy and better sleep quality, regardless of sociodemographic or clinical factors.
Patients with hemophilia A or B, undergoing prophylactic treatment with clotting factor concentrates.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients diagnosed with hemophilia A or B, undergoing prophylactic treatment with short half-life (SHL) and extended half-life (EHL) clotting factor concentrates.
Assessment of treatment burden at the time of the study.
Treatment burden will be assessed using the Spanish version of the Treatment Burden Questionnaire (TBQ). This self-administered multidimensional instrument consists of 15 items that measure the perceived burden of treatment in dimensions such as time spent, emotional impact, physical effort, medical coordination, and interference with daily life. Each item is scored on a Likert scale from 0 (no burden) to 10 (extreme burden). A total score is obtained, with higher values indicating greater perceived burden. This version has demonstrated good internal reliability in the Spanish chronic population (Cronbach's α = 0.89).
Time frame: Screening visit.
Assessment of perceived self-efficacy in health at the time of the study.
Perceived self-efficacy in health will be measured using the Spanish version of the General Self-Efficacy Scale (GSE). This questionnaire consists of 10 items with a 4-point Likert scale (1 = strongly disagree to 4 = strongly agree). It assesses the individual's general belief in their ability to cope with difficulties and manage their health. The total score ranges from 10 to 40, with higher values indicating greater self-efficacy. The scale has shown good internal consistency (Cronbach's α = 0.87) in the Spanish population.
Time frame: Screening visit.
Assessment of adherence to treatment at the time of the study.
Adherence to treatment will be assessed using the Torres scale. This structured self-report, specific for patients with hemophilia, includes 25 items, grouped into 5 dimensions: awareness of the disease, knowledge of sequelae, treatment difficulties, doctor-patient relationship, and treatment of bleeding episodes. This scale has proven to be valid and reliable for assessing adherence in these patients, with good internal consistency across all dimensions. The total score ranges from 0 to 100, with higher values indicating poorer adherence.
Time frame: Screening visit.
Assessment of sleep quality at the time of the study.
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI) in its validated Spanish version. This self-administered questionnaire assesses sleep quality over the last month through 19 items grouped into seven components (latency, duration, efficiency, disturbances, medication use, daytime dysfunction, and subjective sleep quality). Each component is scored from 0 to 3, generating an overall score from 0 to 21, where a score \>5 indicates poor sleep quality. Its test-retest reliability and internal consistency have been adequate (Cronbach's α = 0.81).
Time frame: Screening visit.
Assessment of health locus of control at the time of the study.
Health locus of control will be measured using the Spanish version of the Multidimensional Health Locus of Control Form C (MHLC-C). This scale consists of 18 items that assess the extent to which people attribute control of their health to internal, medical or random factors. It consists of three subscales of 6 items each, scored on a scale from 1 (total disagreement) to 6 (total agreement). Each subscale generates an independent score. Validation in Spanish has shown good internal reliability (Cronbach's α \> 0.70 in all three dimensions).
Time frame: Screening visit.
Assessment of the sociodemographic variable age at the time of the study.
The sociodemographic variable age will be assessed by calculating the age (in months) from the date of birth to the date of assessment.
Time frame: Screening visit.
Assessment of the clinical variable number of weekly infusions of clotting factor concentrates at the time of the study.
The clinical variable number of weekly infusions of clotting factor concentrates will be assessed by calculating the age (in months) from the date of birth to the date of assessment.
Time frame: Screening visit.
Assessment of the sociodemographic variable educational level at the time of the study.
The sociodemographic variable educational level will be assessed using closed-ended questions (primary education / secondary education / university education / postgraduate education).
Time frame: Screening visit.
Assessment of the sociodemographic variable 'living arrangements at the time of the study'.
The sociodemographic variable 'living arrangements' will be assessed using a qualitative variable with three response options: alone / with family / with partner.
Time frame: Screening visit.
Assessment of the clinical variable cohabitation at the time of the study.
The clinical variable type of hospital where treatment is received will be a dichotomous variable, with two response options: national referral hospital-CESUR / regional referral hospital.
Time frame: Screening visit.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in May 2026, 9 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Sep 2025 → May 2026 and completion Oct 2025 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Investigación en Hemofilia y Fisioterapia